Crystal Bennett
Family · Rayville, LANPI 1770839953
Payments from drug & device makers
Across 417 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alkermes, Inc.$670
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$524
- Teva Pharmaceuticals USA, Inc.$429
- Neurocrine Biosciences, Inc.$387
- Takeda Pharmaceuticals U.S.A., Inc.$353
- plus $3K from 29 others
What the payments were for
- Food & beverage$7,09699%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 105 | $1,423 |
| Alkermes, Inc. | 43 | $670 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $524 |
| Teva Pharmaceuticals USA, Inc. | 21 | $429 |
| Neurocrine Biosciences, Inc. | 18 | $387 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $353 |
| Axsome Therapeutics, Inc. | 22 | $328 |
| Sunovion Pharmaceuticals Inc. | 15 | $313 |
| Otsuka America Pharmaceutical, Inc. | 15 | $286 |
| Johnson & Johnson | 14 | $271 |
| Corium, LLC | 14 | $269 |
| Supernus Pharmaceuticals, Inc. | 15 | $268 |
| E.r. Squibb & Sons, L.L.C. | 14 | $260 |
| Lundbeck LLC | 12 | $195 |
| Novo Nordisk | 9 | $147 |
| Pfizer | 8 | $139 |
| Vanda Pharmaceuticals Inc. | 6 | $137 |
| Indivior Inc. | 6 | $121 |
| Idorsia Pharmaceuticals US Inc | 6 | $99 |
| Lilly USA, LLC | 5 | $88 |
| Collegium Pharmaceutical, Inc. | 4 | $59 |
| Astellas Pharma US Inc | 3 | $57 |
| Evofem Biosciences, Inc. | 3 | $52 |
| Ironshore Pharmaceuticals Inc. | 2 | $45 |
| Boehringer Ingelheim | 2 | $34 |
| Eisai Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| AstraZeneca | 1 | $20 |
| Tris Pharma Inc | 1 | $20 |
| IBSA Pharma Inc. | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Genentech USA, Inc. | 1 | $2 |
How this compares
$7,145 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 48 | $49,380 |
| JardianceEmpagliflozin | 37 | $34,014 |
| OzempicSemaglutide | 19 | $18,447 |
| RexultiBrexpiprazole | 11 | $15,545 |
| VeozahFezolinetant | 19 | $10,276 |
| XareltoRivaroxaban | 13 | $7,256 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 11 | $5,904 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $5,345 |
| Varenicline Tartrate | 20 | $3,737 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $1,894 |
| Estradiol (Once Weekly)Estradiol | 13 | $733 |
| Hydroxyzine Pamoate | 26 | $706 |
| Duloxetine Hcl | 50 | $608 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 21 | $601 |
| Testosterone Cypionate | 28 | $589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $88 | $49,38048 claims |
| Boehringer IngelheimJardiance | $34 | $34,01437 claims |
| Novo NordiskOzempic | $147 | $18,44719 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $286 | $15,54511 claims |
| Astellas Pharma US IncVeozah | $57 | $10,27619 claims |
| Johnson & JohnsonXarelto | $271 | $7,25613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Rayville
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.